Fate Therapeutic (FATE) Stock News

Fate Therapeutics (NASDAQ: FATE) reported Q4 and full-year 2025 results and clinical progress on Feb 26, 2026. The company ended 2025 with $205.1 million in cash, projects runway through year-end 2027, and recorded Q4 revenue of $1.4 million. FT819 achieved outpatient dosing across autoimmune indications (15 SLE, 4 SSc, 1 IIM treated) and showed a 3-month improvement in a systemic sclerosis patient. FT836 showed a >50% CEA reduction in a CRC patient without conditioning chemotherapy. Operating expenses declined ~30% in 2025 versus 2024.

Fate Therapeutics (NASDAQ: FATE) granted inducement awards on February 1, 2026 to a newly-hired non-executive employee under its Amended and Restated Inducement Equity Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

The package includes 120,000 non-qualified stock options at an exercise price of $1.19 per share and 90,000 restricted stock units (RSUs). Options vest over four years (25% at one year, remainder monthly over 36 months); RSUs vest 25% each anniversary over four years, subject to continued employment.

Fate Therapeutics (NASDAQ: FATE) announced inducement equity awards granted on January 1, 2026 to newly hired non-executive employees under its Amended and Restated Inducement Equity Plan pursuant to Nasdaq Listing Rule 5635(c)(4).

The company granted a non-qualified stock option for 48,000 shares at an exercise price of $0.98 (NASDAQ close on December 31, 2025) to one new hire and 79,400 restricted stock units (RSUs) to four new hires (one individual received both the option and RSUs). Options vest over four years (25% after one year, then monthly over 36 months). RSUs vest over four years with 25% vesting on each anniversary, subject to continued employment.

Fate Therapeutics (NASDAQ: FATE) presented updated Phase 1 data for off-the-shelf CAR T candidate FT819 and preclinical advances for FT836 and FT839 at ASH 2025. 13 patients enrolled (12 SLE, 1 SSc); 10 SLE patients had ≥1 month follow-up. FT819 showed progressive mean SLEDAI-2K score reductions (DL1: 50% at 3 months, 70% at 6 months; DL2: 65% at 3 months, 78% at 6 months [n=1 at 6 months]), durable B‑cell depletion, meaningful FACIT‑fatigue improvements, no Grade >2 CRS/ICANS/GVHD, and on‑demand dosing from inventory. Company plans to discuss a registrational trial for FT819 in 2026 under RMAT. Preclinical FT836/FT839 data show expanded antigen targeting and conditioning‑free approaches for hematologic and autoimmune indications.

Fate Therapeutics (NASDAQ: FATE) will present at the Piper Sandler 37th Annual Healthcare Conference in New York on Tuesday, December 2, 2025. Company management will participate in a fireside chat at 9:00 AM ET and a cell therapy panel discussion at 12:00 PM ET.

A live webcast of each presentation, if recorded, will be accessible under “Events & Presentations” in the Investors section at www.fatetherapeutics.com, and archived webcasts will be posted on the company website shortly after the event.

Fate Therapeutics (NASDAQ: FATE) reported Q3 2025 results and program updates on Nov 13, 2025. Key clinical progress includes MHRA and EMA authorization to open ex-US FT819 sites and updated Phase 1 FT819 data showing meaningful SLEDAI-2K score reductions (mean −10.7 at 3 months, −14 at 6 months in Regimen A) with no dose-limiting toxicities, no ICANS or GvHD, and only low-grade CRS. First systemic sclerosis patient treated with fludarabine-free conditioning; first FT836 solid tumor patient treated without conditioning. Financials: $225.7M cash (Sept 30, 2025), Q3 revenue $1.7M, and Q3 operating expenses $36.5M; company projects runway through year-end 2027 with $226M in cash, cash equivalents, and investments.

Fate Therapeutics (NASDAQ: FATE) announced on November 1, 2025 that it granted restricted stock units representing 34,700 shares to three newly hired non-executive employees as inducement awards under its Amended and Restated Inducement Equity Plan.

The grants were approved by the Compensation Committee and were made in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs vest over four years with 25% vesting on each anniversary of the grant date, subject to continuous employment through each vesting date.

Fate Therapeutics (NASDAQ: FATE) reported updated Phase 1 data for off-the-shelf CAR T product FT819 in 10 treatment-refractory moderate-to-severe systemic lupus erythematosus (SLE) patients as of a Sept 25, 2025 data cut.

Key findings: single-dose FT819 produced rapid CD19+ B-cell depletion, immune remodeling toward a naïve B-cell repertoire, durable clinical responses including two complete renal responses (CRR) at 6 months and one patient in steroid-free DORIS at 15 months, low-grade CRS only, no ICANS or GvHD, and potential for same-day discharge and outpatient administration.

Fate Therapeutics (NASDAQ: FATE) appointed Kamal Adawi as Chief Financial Officer effective October 20, 2025. Mr. Adawi brings more than 20 years of life‑sciences financial leadership, including over 10 years as CFO and experience leading Exagen through an IPO. The company will grant an inducement package: a 375,000 non‑qualified stock option exercisable at the closing price on October 20, 2025, vesting over four years, and 75,000 restricted stock units vesting in four annual tranches starting November 1, 2026. Grants are made under the Amended and Restated Inducement Equity Plan in accordance with Nasdaq Listing Rule 5635(c)(4).